International Extranodal Lymphoma Study Group (ielsg)
Clinical trials sponsored by International Extranodal Lymphoma Study Group (ielsg), explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can PET scans better predict lymphoma outcomes? Results expected Oct 2026 (estimated)
- New hope for lymphoma patients who Can't take chemo Results expected Dec 2026 (estimated)
- Scientists dive into DNA of rare lymphoma to predict outcomes Results expected Dec 2026 (estimated)
- New hope for marginal zone lymphoma: Chemo-Free combo shows promise Results expected Jun 2027 (estimated)
- New drug cocktail aims to control Hard-to-Treat lymphoma Results expected Sep 2027 (estimated)
-
Could an antibiotic beat eye cancer? new trial tests doxycycline for lymphoma
Disease control CompletedThis phase 2 trial tested the antibiotic doxycycline as a first treatment for a rare type of eye lymphoma (OAMZL) that may be linked to a bacterial infection. 44 newly diagnosed patients took doxycycline for several months. The goal was to see if eradicating the infection could c…
Phase 2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New trial tests stronger chemo cocktails and stem cell transplants for brain cancer
Disease control CompletedThis phase 2 trial tested different combinations of high-dose chemotherapy drugs, with or without the targeted drug rituximab, in 227 patients newly diagnosed with primary CNS lymphoma. After initial chemotherapy, patients who responded well were randomly assigned to receive eith…
Phase 2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC